Inflammatory profile in unstable angina versus stable angina in patients undergoing percutaneous interventions

American Heart Journal

Volumn 136, Issue 2, 1998, Pages 357-361

  Yazdani, Shahram ^b   Simon, Alan D ^b   Vidhun, Raghuraman ^b   Gulotta, Carolyn ^b   Schwartz, Allan ^b   Rabbani, LeRoy E ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0031871091     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1998.v136.90408     Document Type: Article

References (30)

1. Yarnell JWG, Baker IA, Sweetnam A, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991;88:836-44.
2. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;90:36-44.
3. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Atherosclerosis 1989;9:567-78.
4. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992;12:206-11.
5. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-75.
6. Liuzzo G, Biasucci LM, Gallimore R, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
7. de Beer FC, Hind CR, Fox KM, Allan RN, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial infarction. Br Heart J 1982;47:239-43.
8. Biasucci LN, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;95:874-7
9. Le J, Vilcek J. Interleukin 6: a multifactorial cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588-602.
10. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
11. Kruskal JB, Commerford PJ, Franks JJ, Kirsh RE. Fibrin and fibrinogen related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 1987;317:1361-5.
12. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 1989;19:689-94.
13. Van der Meer J, Helle M, Aarden L. Comparison of the effects of recombinant interleukin 6 and recombinant interleukin 1 on nonspecific resistance to infection. Eur J Immunol 1989;19:413-6.
14. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83-4.
15. Gauldie J, Richards C, Hamish D, Lansdorp P, Baumann H. Interferon beta2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987;84:7251-5.
16. Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 1988;167:1253-8.
17. Beagley KW, Eldrige JH, Lee F, Kiyono H, Everson MP, Koopman WJ, et al. Interleukins and Ig A synthesis: human and murine interleukin 6 induce high rate Ig A secretion in IgA-committed B cells. J Exp Med 1989;169:2133-48.
18. van der Poll T, Levi M, Hack CE, ten Cate U, van Deventer SJH, Eerenberg AJM, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-9.
19. Newman FJ, Ott l, Gawaz M, Richardt G, Holzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
20. Massignon D, Lepape A, Bienvenu J, Barbier Y, Boileau C, Coeur P. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state. Haemostasis. 1994;24:36-48.
21. Mestries JC, Kruihof EK, Gascon MD, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994;5:275-81.
22. Stouthard J, Levi M, Hack E, Veenhof C, Romijn H, Sauerwein H, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996;76:738-42.
23. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral monocytes to synthesize tissue factor. Blood 1993;82:513-20.
24. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987;56:234-48.
25. Lachman LB, Dinarello CA, Llansa ND, Fidler U. Natural and recombinant human interleukin 1-a is cytotoxic for human melanoma cells. J Immunol 1986;136:3098-102.
26. Tosado G, Seamon KB, Goldman ND, Sehgal PB, May LT, Washington GC, et al. Monocyte-derived human B-cell growth factor identified as interferon-beta2 (BSF-2, IL-6). Science 1988;239:502-4.
27. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990;7:147-59.
28. Dinarello CA, Biological bases for interleukin-1 in disease. Blood 1996;87:2095-147
29. Steele P, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-12.
30. Van Belle E, Tio FO, Couffindal T, Maillard L, Passeri J, Isner JM. Stent endothelialization: time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation 1997;95:438-48.